Skip to main content
Equibles
HIMS logo

HIMS · Hims & Hers Health, Inc.

Track HIMS — free

Use HIMS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$27.71 -0.11 (-0.40%) At close · Sep 4
S&P 400 member Russell 2000 member Rebalance outlook locked
Customer concentration — top customer 10% of receivables

One customer — 10% of receivables (December 31, 2025)

“As of December 31, 2025, one customer or partner individually represented more than 10% of accounts receivable.”

4 customers — 10% of receivables (December 31, 2024)

“As of December 31, 2024, four customers or partners individually represented more than 10% of accounts receivable.”
View the 10-K filed Feb 23, 2026
Market Cap
$6.51B
Shares
233.31M

HIMS metrics

71 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$27.71
Market cap
$6.51B

Price action

19 metrics
Price change (1W)
-12.1%
Price change (30D)
-6.2%
Price change (3M)
-0.7%
Price change (6M)
+75.2%
Price change (YTD)
-14.3%
Price change (1Y)
-37.4%
Trailing year
Price change (5Y)
+238.9%
52-week high
$62.76
52-week low
$14.52
Change from 52-week high
-55.7%
Change from 52-week low
+91.6%
Annualized volatility
93.4%
Beta
2.9
RSI (14D)
43.6
Price vs SMA 50
-12.3%
Price vs SMA 200
-2.1%
Avg volume (3M)
15.29M
Relative volume
0.8
Average dollar volume
$478.93M

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
233.31M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2.5×
reciprocal yield 39.6%
P / book
20.1
reciprocal yield 5.0%
FCF yield
0.9%
TTM · current market cap
Buyback yield
1.4%
P / FCF
105.6
reciprocal yield 0.9%
P / operating cash flow
24.7
reciprocal yield 4.0%
Earnings yield
-2.2%

Historical valuation

8 metrics
P / E historical average (3Y)
89.0×
reciprocal yield 1.1%
P / E historical average (5Y)
89.0×
reciprocal yield 1.1%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-10

Profitability

9 metrics
Gross margin
68.4%
Operating margin
-6.0%
Trailing 12 months
Net margin
-5.5%
Gross profit (TTM)
$1.76B
Operating profit (TTM)
−$154.52M
Net income (TTM)
−$142.03M
Trailing 12 months
Diluted EPS (TTM)
$-0.63
FCF margin
2.4%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+38.2%
Year over year
Net income growth YoY
-303.0%
Revenue (TTM)
$2.58B
Trailing 12 months
EPS growth YoY
-317.6%
Shares change YoY
-9.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+64.5%
Revenue CAGR (5Y)
+73.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-43.8%
Return on assets
-3.9%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
−$67.33M
Free cash flow (TTM)
$61.65M
Quick ratio
0.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$609.81M
Total assets
$3.63B
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$263.45M
Capital expenditures (TTM)
$201.80M
R&D (TTM)
—
SG&A (TTM)
$175.65M
Stock compensation (TTM)
$153.64M
R&D / revenue
—
Stock compensation / revenue
6.0%

Ownership (13F)

3 metrics
13F filers
523
13F filer change QoQ
+78
Institutional ownership
94.5%

Short interest

3 metrics
Short interest
25.1%
Latest settlement · 4.5 days to cover
Days to cover
4.5d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$7.31M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1773751 CUSIP 433000106 13F (30d) 346 filings 344 filers Visit website Investor relations